Beyond the Snapshot: A New Wearable Unlocks the Body’s Resilience Signal

MENLO PARK, CA – June 08, 2026 – In the pursuit of lasting value and performance, we often look for signals that cut through the noise. For decades, medicine has attempted to understand the body’s complex systems using the equivalent of static photographs: a single blood draw, a one-off saliva sample. This approach captures a moment but misses the story. Today, at the American Diabetes Association's 86th Scientific Sessions, a Stanford spinout named Adaptyx Biosciences just premiered the full-length film.

The company presented the first-ever continuous, multi-day data of free cortisol from a human wearing a simple sensor. Cortisol, often dubbed the “stress hormone,” is in reality one of the body’s master regulators, a signal that dictates metabolism, immunity, cardiovascular function, and sleep. By finally making this dynamic signal visible, Adaptyx is offering more than a new diagnostic tool; it is providing a new language to understand the very mechanics of human resilience.

The Tyranny of the Static Test

To grasp the significance of this development, one must first understand the profound limitations of the status quo. Cortisol is a hormone of rhythm. It naturally peaks in the morning to wake us, ebbs throughout the day, and hits a low point overnight to facilitate rest and repair. Disruptions to this rhythm—a flattened curve, a delayed peak, chronically elevated levels—are implicated in a vast array of chronic conditions.

“Cortisol is one of the most consequential hormones in the human body,” said Vijit Sabnis, Ph.D., co-founder and CEO of Adaptyx. “Clinical care has treated the downstream effects, including diabetes, hypertension, and depression, without ever being able to monitor the upstream signal driving much of the response. Adaptyx built the device that finally does.”

Until now, clinicians have been hamstrung. A morning blood test might miss the crucial cortisol awakening response. A late-night saliva test can’t confirm the depth of the overnight nadir. A 24-hour urine collection averages the entire day into a single, uninformative number. It’s like trying to assess a company’s annual performance by looking at a single day’s stock price. The underlying patterns of strength and weakness—the very essence of resilience—remain invisible. This data poverty has forced medicine to be reactive, treating the symptoms of cortisol dysregulation without ever truly seeing the cause.

Engineering a Continuous Conversation

The challenge of continuously monitoring cortisol is immense. The hormone is present at concentrations more than a million times lower than glucose, rendering the enzymatic sensors used in continuous glucose monitors (CGMs) ineffective. Solving this required a paradigm shift in biosensing.

Adaptyx’s breakthrough, born from over 18 years of research at Stanford, is a platform built on programmable, DNA-based molecular switches. “It requires a fundamentally new approach,” explained Alex Yoshikawa, Ph.D., co-founder and Chief Science Officer. He described how these synthetic DNA structures are designed to reversibly bind to cortisol, changing shape to generate a continuous electrical signal. This reversible binding is key, allowing the sensor to track rising and falling levels with minute-level resolution over multiple days.

To validate this novel approach, the company conducted two pivotal first-in-human studies. In the first, a controlled challenge with an oral dose of hydrocortisone, the wearable’s readings showed strong concordance with the gold-standard lab method (LC-MS/MS) for measuring cortisol in blood. This anchored the sensor's accuracy to established clinical benchmarks. The second study involved overnight monitoring of individuals during normal activity, where the sensor successfully captured the body's natural cortisol rhythm, including the morning rise and overnight low—the very dynamics that static tests miss.

This isn't just an incremental improvement; it's a categorical leap. It's the difference between knowing a factory's total output for the year and having a real-time dashboard of every production line, 24/7.

The Makings of a Winner: Strategy, Science, and Scope

A disruptive technology is only as valuable as the strategy that brings it to market. Here, Adaptyx exhibits the identifying marks of a winner. The company is built on a formidable intellectual property foundation, with an exclusive license to nine Stanford patents and another 18 filed independently. It is backed by $23 million in seed funding and a clear regulatory plan, targeting a Class II FDA pathway.

Its initial go-to-market strategy is shrewdly focused on areas of acute, unmet clinical need. The first targets are adrenal diseases like Cushing's syndrome and adrenal insufficiency, where cortisol is the central pathology. The second, and far larger, opportunity is in cardiometabolic disease. Millions of patients with difficult-to-control type 2 diabetes, treatment-resistant hypertension, and other metabolic disorders have underlying cortisol dysregulation that sabotages their treatment. For these patients, continuous cortisol data could finally provide the missing piece of the puzzle, enabling truly personalized care.

The broader vision, however, is what signals the potential for permanence. The DNA-switch technology is a platform, not a single-product trick. Cortisol is just the first analyte. The company plans to develop sensors for other hormones, therapeutic drugs, and key biomarkers. “The same sensing chemistry extends to other hormones and molecular biomarkers as the platform expands,” Sabnis noted, envisioning a future where a multi-analyte sensor provides an ever-clearer, more actionable picture of the body's internal state.

This platform potential, combined with the win at the 2026 American Diabetes Association Innovation Challenge, suggests that the broader industry recognizes the tectonic shift Adaptyx represents. The ability to move from treating downstream effects to modulating upstream signals is the holy grail of proactive, preventative medicine. By making the body's intricate hormonal conversations legible, Adaptyx is not just creating a new market; it is providing a foundational technology for a more resilient and informed approach to human health.